Metraipolis › archive › dc_d8aee806bf2d

Clinical outcomes of trifluridine/tipiracil plus bevacizumab versus trifluridine/tipiracil or regorafenib in metastatic colorectal cancer: a multicenter… — Europe PMC PMID:41894981

Source: Europe PMC (en)
Original: https://europepmc.org/article/MED/41894981
DOI: 10.1016/j.esmoop.2026.106907
License (as archived): solo-consultazione
Archived: 2026-11-03T21:13:34.830Z
SHA-256 of the archived text: a717b67613424ebb699672bde07ebf9ce664a0fe6256b50ab96fd0904cd0f117
Stable URL of this page: https://metraipolis.com/documento/dc_d8aee806bf2d

How to cite

Clinical outcomes of trifluridine/tipiracil plus bevacizumab versus trifluridine/tipiracil or regorafenib in metastatic colorectal cancer: a multicenter… — Europe PMC PMID:41894981 — Europe PMC (en), https://europepmc.org/article/MED/41894981 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_d8aee806bf2d (Metraipolis archive dc_d8aee806bf2d, sha256 a717b67613424ebb699672bde07ebf9ce664a0fe6256b50ab96fd0904cd0f117)

BibTeX

@misc{dcd8aee806bf2d,
  title = {Clinical outcomes of trifluridine/tipiracil plus bevacizumab versus trifluridine/tipiracil or regorafenib in metastatic colorectal cancer: a multicenter… — Europe PMC PMID:41894981},
  howpublished = {Europe PMC (en)},
  url = {https://europepmc.org/article/MED/41894981},
  note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_d8aee806bf2d; sha256 a717b67613424ebb699672bde07ebf9ce664a0fe6256b50ab96fd0904cd0f117},
  year = {2026}
}

Archived text

The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/41894981. Agents can read the archived copy with the MCP tool read_document.